compounded semaglutide lawsuit news today The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new (Wegovy) weight-loss pill from the Ozempic Lawsuit [July 2026 Update]

Moreover, as generic forms of GLP-1 drugs arrive post-patent expiry, and oral substitutes replace current injectables,54 broader access and lower drug costs could improve claims dynamics

Thats why we proudly offer Semaglutide GLP-1 therapy for medically supervised weight loss

This extended half-life means that once you reach steady-state plasma concentrations (typically after 45 weekly injections), your body maintains therapeutic levels throughout the entire week

This is called prior authorization, and it means your doctor will need to submit a form to your insurance company showing that Ozempic is "medically necessary" for your health